The European Medicines Agency (EMA) has added an extremely rare neurological disease, Guillain-Barré syndrome (GBS), as a possible side effect of AstraZeneca’s Covid-19 vaccine, according to a regular safety update published on Wednesday by the institution, Reuters reports .
According to the EMA, there is “at least a reasonable possibility” of a causal link between GBS and the AstraZeneca vaccine, known as Vaxzevria, after 833 cases of GBS were reported after administration of 592 million doses of this vaccine. on July 31.
The EMA included this side effect in the “very rare” category, where the frequency of side effects is lowest, and pointed out that the benefits of the vaccine outweigh the risks.
The US Food and Drug Administration has added a warning about Guillain-Barré syndrome as a possible side effect of Johnson & Johnson’s Covid-19 vaccine.
Both vaccines use viral vector technology and have not been associated with rare cases of blood clots.
The EMA has also associated some less serious side effects with vaccines developed by Johnson & Johnson, Moderna and AstraZeneca.
– .
